Obermatt
See Similar Stocks →

Disc Medicine

NMQ:IRON · US2546041011
BiotechnologySmall

360° View

5
Price/Sales22
Price/Earnings70
Price/Book37
Dividend Yield1
Revenue Growth—
Profit Growth15
Capital Growth17
TSR 52w34
Leverage50
Liquidity20
Refinancing61
Combined1
Analyst Opinions74
Pro Holdings95
Opinion Changes50
Market Pulse85

Profile

CountryUSA
IndustryBiotechnology
SizeSmall
TypePublic Company
ExchangeNASDAQGM
Employees145
Websitediscmedicine.com
ISINUS2546041011
Last UpdateApr 2, 2026
Index & Theme
Chronic DiseasesHematologyInflammationBiotechnologyHealth CareMedicalPharmaceuticalTherapeutics

Description

Disc Medicine, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases. The company has assembled a portfolio of clin…

Analysis

Disc Medicine's 360° View rank of 5 places it among the weakest overall — better than 5% of its true peers.

It's lagging on growth (6) and on the expensive side (38). On safety it is highly leveraged (19), and the market shows strongly positive sentiment (99). Taken together, its Combined rank of 1 reads as among the weakest overall.

360° rank · history

1007550250
5
2026

All-time high

45

Mar 2026

All-time low

5

Jun 2026

Average rank

25

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
22
—
—
—
Price/Earnings
70
—
—
—
Price/Book
37
—
—
—
Dividend Yield
1
—
—
—
Value (overall)
38
—
—
—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Disc Medicine with its peers
Mink Therapeutics
NAQ:INKT
—
CountryUSA
IndustryBiotechnology
SizeX-Small
Full Stock Analysis →
Nurix Therapeutics
NMQ:NRIX
18
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Geron
NSQ:GERN
22
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Esperion Therapeutics
NMQ:ESPR
9
CountryUSA
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Incyte
NSQ:INCY
95
CountryUSA
IndustryBiotechnology
SizeLarge
Full Stock Analysis →
Mineralys Therapeutics
NSQ:MLYS
21
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →